Patents by Inventor Fumihiko Yasui

Fumihiko Yasui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT VACCINIA VIRUS
    Publication number: 20230295655
    Abstract: The present invention provides a recombinant vaccinia virus serving as a clinically usable preventive vaccine for COVID-19 (vaccine for SARS-CoV-2), etc. The recombinant vaccinia virus of the present invention is characterized by comprising the whole or part of cDNA encoding nonstructural proteins or structural protein derived from SARS-CoV-2, and an expression promoter.
    Type: Application
    Filed: July 30, 2021
    Publication date: September 21, 2023
    Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, Shiga University of Medical Science
    Inventors: Michinori KOHARA, Fumihiko YASUI, Yasushi ITOH, Koji ISHII
  • STRAIN DIS-DERIVED RECOMBINANT VACCINIA VIRUS HAVING NOVEL INFLUENZA VIRUS-DERIVED HEMAGGLUTININ PROTEIN GENE
    Publication number: 20230174586
    Abstract: Provided are: a recombinant vaccinia virus which is effective for the prevention of the development of a disease by the infection by H7 avian influenza virus and has high safety; and a vaccine against H7 avian influenza virus, which comprises the recombinant vaccinia virus. The recombinant vaccinia virus according to the present invention is a recombinant vaccinia virus having such a structure that an expression promoter and the full length or a part of cDNA encoding hemagglutinin protein of H7 avian influenza virus are contained in the genome for vaccinia virus strain DIs.
    Type: Application
    Filed: November 14, 2019
    Publication date: June 8, 2023
    Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, SHIGA UNIVERSITY OF MEDICAL SCIENCE
    Inventors: Fumihiko YASUI, Michinori KOHARA, Kenzaburo YAMAJI, Yasushi ITOH, Kazumasa OGASAWARA, Koji ISHII
  • DENGUE VIRUS VACCINE
    Publication number: 20220152187
    Abstract: The present invention provides a recombinant Vaccinia virus as a dengue virus vaccine that can be used as a therapeutic or prophylactic agent in the clinic. This recombinant Vaccinia virus is characterized by including: all or part of a cDNA that encodes a non-structural protein from a dengue virus; and an expression promoter.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, KAGOSHIMA UNIVERSITY, NAGASAKI UNIVERSITY
    Inventors: Michinori KOHARA, Fumihiko YASUI, Daisuke YAMANE, Kyoko KOHARA, Kouichi MORITA, Yasuhiro YASUTOMI, Koji ISHII
  • MEDICATION FOR INFLUENZA
    Publication number: 20200345800
    Abstract: A medication for preventing or treating influenza, said medication including an inactivated influenza virus or a recombinant vaccinia virus that includes, within the genome of the vaccinia virus DIs strain, an expression promoter and all or a portion of DNA coding for an influenza virus-derived protein.
    Type: Application
    Filed: August 10, 2018
    Publication date: November 5, 2020
    Inventors: Fumihiko Yasui, Michinori Kohara
  • RECOMBINANT VACCINIA VIRUS HAVING HEMAGGLUTININ PROTEIN GENES DERIVED FROM NOVEL INFLUENZA VIRUSES
    Publication number: 20180161421
    Abstract: Provided are a highly-safe recombinant vaccinia virus that is effective in preventing the onset of symptoms due to infection by novel influenza viruses, and a vaccine for the novel influenza viruses containing the recombinant vaccinia virus. This recombinant vaccinia virus is capable of expressing the hemagglutinin protein genes of the novel influenza virus. This novel influenza vaccine contains the recombinant vaccinia virus.
    Type: Application
    Filed: January 29, 2018
    Publication date: June 14, 2018
    Inventors: Michinori KOHARA, Fumihiko YASUI, Toshio MURAKAMI, Hiroshi KIDA, Yoshihiro SAKODA
  • RECOMBINANT VACCINIA VIRUS HAVING HEMAGGLUTININ PROTEIN GENES DERIVED FROM NOVEL INFLUENZA VIRUSES
    Publication number: 20130288338
    Abstract: Provided are a highly-safe recombinant vaccinia virus that is effective in preventing the onset of symptoms due to infection by novel influenza viruses, and a vaccine for the novel influenza viruses containing the recombinant vaccinia virus. This recombinant vaccinia virus is capable of expressing the hemagglutinin protein genes of the novel influenza virus. This novel influenza vaccine contains the recombinant vaccinia virus.
    Type: Application
    Filed: October 13, 2011
    Publication date: October 31, 2013
    Applicants: TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventors: Michinori Kohara, Fumihiko Yasui, Toshio Murakami, Hiroshi Kida, Yoshihiro Sakoda